Intranasal Administration of Catechol-Based Pt(IV) Coordination Polymer Nanoparticles for Glioblastoma Therapy

Cisplatin has been described as a potent anticancer agent for decades. However, in the case of glioblastomas, it is only considered a rescue treatment applied after the failure of second-line treatments. Herein, based on the versatility offered by coordination chemistry, we engineered nanoparticles...

Descripción completa

Detalles Bibliográficos
Autores: Mao, Xiaoman, Calero-Perez, Pilar|||0000-0001-9370-3757, Montpeyó, David|||0000-0002-0327-2015, Bruna, Jordi|||0000-0001-6895-5047, Yuste, Victor José|||0000-0001-5322-9261, Candiota Silveira, Ana Paula|||0000-0002-1523-6505, Lorenzo Rivera, Julia|||0000-0001-5659-6008, Novio, Fernando|||0000-0002-1517-3612, Ruiz-Molina, Daniel|||0000-0002-6844-8421
Tipo de recurso: artículo
Fecha de publicación:2022
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:258094
Acceso en línea:https://ddd.uab.cat/record/258094
https://dx.doi.org/urn:doi:10.3390/nano12071221
Access Level:acceso abierto
Palabra clave:Nanoscale coordination polymers
Platinum
Catechol
Intranasal administration
Glioblastoma
Preclinical studies
GL261 GB
Magnetic resonance imaging
Descripción
Sumario:Cisplatin has been described as a potent anticancer agent for decades. However, in the case of glioblastomas, it is only considered a rescue treatment applied after the failure of second-line treatments. Herein, based on the versatility offered by coordination chemistry, we engineered nanoparticles by reaction of a platinum (IV) prodrug and iron metal ions showing in vitro dual pH- and redox-sensitivity, controlled release and comparable cytotoxicity to cisplatin against HeLa and GL261 cells. In vivo intranasal administration in orthotopic preclinical GL261 glioblastoma tumor-bearing mice demonstrated increased accumulation of platinum in tumors, leading in some cases to complete cure and prolonged survival of the tested cohort. This was corroborated by a magnetic resonance imaging follow-up, thus opening new opportunities for intranasal glioblastoma therapies while minimizing side effects. The findings derived from this research showed the potentiality of this approach as a novel therapy for glioblastoma treatment.